NASH Observatory

The American Heart Association has defined ideal cardiovascular health based on seven risk factors (Life’s Simple 7 – LS7) that people can improve through lifestyle changes: smoking status, physical activity, weight, diet, blood glucose, cholesterol, and blood pressure. NAFLD is considered as a risk factor for cardiovascular disease...

Hepatic steatosis and gallstone disease are highly prevalent in the general population; the shared risk factors are age, ethnicity, obesity, insulin resistance, metabolic syndrome, atherosclerosis, risk of cardiovascular disease, and mortality. The presence of insulin resistance is the critical element in this association because it represents...

Metabolic dysfunction in liver disease is reflected in the biocomposition of exhaled breath. Analysis of volatile organic compounds (VOCs) in exhaled breath, ‘volatomics’, provides opportunities for non-invasive biomarker discovery and novel mechanistic insights into a variety of diseases. The purpose of this pilot study by R. Sinha et al...

Patients with hepatocellular carcinoma (HCC)-NAFLD are usually older, with more morbidities (especially cardiovascular diseases and metabolic disorders) and have advanced disease at the diagnosis due to the absence of surveillance. Patients with HCC-NAFLD unlikely underwent curative treatments...

Non-alcoholic steatohepatitis (NASH) leads to cirrhosis and is associated with a substantial socioeconomic burden, which, coupled with rising prevalence, is a growing public health challenge. Nevertheless, there has been little research into the socioeconomic burden associated with NASH....

Mitochondrial dysfunction plays a central role in nonalcoholic fatty liver disease (NASH). Zhao et al. report that the mitochondrial circular RNA steatohepatitis-associated circRNA ATP5B regulator (SCAR) account for a considerable fraction of downregulated circRNAs in NASH fibroblasts liver fibroblasts from patients with NASH...

Our current understanding of the natural history of NAFLD is incomplete due to a limited knowledge of patient and clinical factors in addition to fibrosis stages that are associated with progression to advanced liver diseases and death. Thus, the aims of the analysis by Ali Canbay et al. (Department of Internal Medicine, Ruhr-University, Bochum, Germany) were...

In this meta-analysis by A. Lin et al. based on data pooled from all 27 studies, the prevalence of NAFLD among Inflammatory Bowel Disease was 32% (95% CI, 24%-40%) with substantial heterogeneity (I2 = 98%). This prevalence of NAFLD among IBD patients is statistically significantly higher than the prevalence of NAFLD in the general population (25.2%; P < 0.001)...

The goal of K. Cusi et al. (Division of Endocrinology, Diabetes and Metabolism, University of Florida, USA) was to review evidence about the complex association between NAFLD and T2DM, and highlight the potential for disease co-management with the available...